Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mivebresib + venetoclax
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**mivebresib + venetoclax** is an investigational combination therapy for relapsed/refractory acute myeloid leukemia (AML). Mivebresib (ABBV-075) is a potent, oral, small-molecule pan-bromodomain and extraterminal (BET) inhibitor that targets BET family proteins, epigenetic readers involved in the regulation of oncogenic transcriptional programs[1][2][4]. Venetoclax is a selective small-molecule inhibitor of the antiapoptotic protein BCL-2, which disrupts leukemic stem cell survival and causes apoptosis in cancer cells[2][4]. The combination exploits the synergistic antileukemic activity: BET inhibition disrupts cancer-related gene expression and enhances cell sensitivity to apoptosis, while BCL-2 inhibition directly induces programmed cell death. This dual mechanism is being evaluated based on its preclinical and early clinical antitumor effects in AML[1][2][4][5].
- Other names
- pan-BET inhibitor + BCL-2 inhibitorMIV-Ven
02
Targets
Bcl-w (B-cell lymphoma 2-like 2)BRDT (Bromodomain testis-specific protein)BRD4 (Bromodomain-containing protein 4)BRD2 (Bromodomain-containing protein 2)BCL2L1 (B-cell lymphoma-extra large protein)BRD3 (Bromodomain-containing protein 3)
Beyond the preview
Go deeper on mivebresib + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mivebresib + venetoclax.